OncoMatch/Clinical Trials/NCT06688305

68Ga-NI-FAPI PET/CT: First-in-human Study

Is NCT06688305 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies 68Ga-NI-FAPI for malignant neoplasm.

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06688305Data as of Jun 2026Location: China

Treatment: 68Ga-NI-FAPI — 68Ga-NI-FAPI is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole (NI)-moiety and a FAP-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-NI-FAPI PET/CT in patients with different types of cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

68Ga-NI-FAPI

Cancer type

Tumor Agnostic

Demographics

Ages ≤ 80

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06688305 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 80 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify